FDA rejects Astellas' effort to support longer use of Izervay 

The FDA has denied Astellas’ attempt to bolster the label for its vision loss treatment Izervay with additional two-year data. Izervay, the centerpiece of Astellas’ $5.9 billion acquisition of Iveric Bio, was ...